IGF1R and neuroblastoma: Decreasing the expression of IGF1R [34] or AKT2 [12] in neuroblastoma cells decreases proliferation, migration, and invasion, validating the IGF1R/PI3 kinase/AKT pathway as a potential therapeutic target in neuroblastoma.